Chugai Pharmaceutical revenue and financials
¥6,101.00Change from previous close: −0.31%Absolute change: −¥19.00
In the fiscal year ended December 2025, Chugai Pharmaceutical reported revenue of ¥1.26T (+7.46% year over year). Net income was ¥434.01B, a net margin of 34.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +7.46%
- 2025 vs 2024
- Net income growth
- +12.06%
- 2025 vs 2024
- Net margin
- 34.5%
- 2024: 33.1%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|
| Total assets | 2,449,914 | 2,468,595 | 2,278,347 |
| Current assets | 1,704,189 | 1,740,758 | 1,619,532 |
| Cash and equivalents | 390,439 | 426,602 | 497,088 |
| Short-term investments | 572,134 | 553,094 | 530,521 |
| Inventory | 317,580 | 276,848 | 235,526 |
| Net property, plant and equipment | 503,477 | 479,481 | 471,346 |
| Other intangible assets | 59,277 | 54,539 | 33,292 |
| Current liabilities | 392,189 | 411,077 | 268,276 |
| Accounts payable | 160,700 | 127,247 | 78,417 |
| Total liabilities | 422,251 | 442,863 | 293,220 |
| Total equity (incl. minority) | 2,027,663 | 2,025,732 | 1,985,127 |